Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía Rodríguez, José Francisco 
dc.contributor.authorBardán García, Belén 
dc.contributor.authorJUIZ GONZALEZ, PEDRO MIGUEL 
dc.contributor.authorVilariño Maneiro, Laura 
dc.contributor.authorÁlvarez Díaz, Hortensia 
dc.contributor.authorMariño Callejo, Ana Isabel 
dc.date.accessioned2022-03-17T08:20:24Z
dc.date.available2022-03-17T08:20:24Z
dc.date.issued2020
dc.identifier.issn2079-6382
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/33375237es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16312
dc.description.abstractOBJECTIVE: To evaluate clinical and antibiotic resistance impact of carbapenems stewardship programs. METHODS: descriptive study, pre-post-intervention, between January 2012 and December 2019; 350-bed teaching hospital. Prospective audit and feedback to prescribers was carried out between January 2015 and December 2019. We evaluate adequacy of carbapenems prescription to local guidelines and compare results between cases with accepted or rejected intervention. Analysis of antibiotic-consumption and hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs) was performed. RESULTS: 1432 patients were followed. Adequacy of carbapenems prescription improved from 49.7% in 2015 to 80.9% in 2019 (p < 0.001). Interventions on prescription were performed in 448 (31.3%) patients without carbapenem-justified treatment, in 371 intervention was accepted, in 77 it was not. Intervention acceptance was associated with shorter duration of all antibiotic treatment and inpatient days (p < 0.05), without differences in outcome. During the period 2015-2019, compared with 2012-2014, decreased meropenem consumption (Rate Ratio 0.58; 95%CI: 0.55-0.63), candidemia and hospital-acquired MDR BSIs rate (RR 0.62; 95%CI: 0.41-0.92, p = 0.02), and increased cefepime (RR 2; 95%CI: 1.77-2.26) and piperacillin-tazobactam consumption (RR 1.17; 95%CI: 1.11-1.24), p < 0.001. CONCLUSIONS: the decrease and better use of carbapenems achieved could have clinical and ecological impact over five years, reduce inpatient days, hospital-acquired MDR BSIs, and candidemia, despite the increase in other antibiotic-consumption.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshCarbapenems*
dc.subject.meshCandidemia*
dc.titleLong-Term Carbapenems Antimicrobial Stewardship Programen
dc.typeJournal Articlees
dc.authorsophosGarcía-Rodríguez, José Francisco;Bardán-García, Belén;Juiz-González, Pedro Miguel;Vilariño-Maneiro, Laura;Álvarez-Díaz, Hortensia;Mariño-Callejo, Ana
dc.identifier.doi10.3390/antibiotics10010015
dc.identifier.pmid33375237
dc.identifier.sophos36383
dc.issue.number1es
dc.journal.titleAntibiotics (Basel, Switzerland)es
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Farmaciaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Medicina Internaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Microbioloxíaes
dc.relation.publisherversionhttps://mdpi-res.com/d://attachment/antibiotics/antibiotics-10-00015/article://deploy/antibiotics-10-00015.pdfes
dc.rights.accessRightsopenAccess
dc.subject.decscarbapenems*
dc.subject.decscandidemia*
dc.subject.keywordCHUFes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number10es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional